Financial Performance - The company reported a revenue of CNY 166,110,936.93 for the first half of 2016, a decrease of 24.64% compared to CNY 220,430,538.40 in the same period last year[20]. - Net profit attributable to shareholders was CNY 15,942,470.88, down 49.95% from CNY 31,852,480.32 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was CNY 15,813,537.87, a decrease of 46.23% compared to CNY 29,406,980.32 in the previous year[20]. - Basic and diluted earnings per share were both CNY 0.0314, reflecting a 50% decrease from CNY 0.0628 in the previous year[20]. - The weighted average return on equity was 1.70%, down from 3.62% year-on-year, indicating a decline in profitability[20]. - The company's operating revenue for the reporting period was ¥166,110,936.93, a decrease of 24.64% compared to the same period last year, primarily due to adjustments in the pharmaceutical distribution business of its subsidiary, Jia Ying Pharmaceutical, and a decline in sales revenue from Jinsha Pharmaceutical[30]. - The net profit for the period was ¥15,942,470.88, down 49.95% year-on-year, attributed to the same factors affecting revenue[31]. - The company's operating profit decreased to CNY 19,047,283.72, down 46.6% from CNY 35,515,837.42 in the same period last year[117]. - The company reported a total profit of CNY 19,199,002.24, down 50.5% from CNY 38,745,837.42 in the same period last year[117]. Cash Flow and Investments - The company experienced a net cash flow from operating activities of CNY -5,296,722.14, an improvement of 15.23% from CNY -6,248,424.50 in the same period last year[20]. - The company reported a significant decline in cash flow from investment activities, with a net cash outflow of ¥6,745,112.35, a decrease of 403.08% year-on-year[31]. - The net cash flow from investing activities was -6,745,112.35 yuan, a decline from a positive 2,225,530.13 yuan in the previous period[125]. - Cash inflow from financing activities totaled 19,294,285.37 yuan, while cash outflow was 7,338,864.93 yuan, resulting in a net cash flow of -7,338,864.93 yuan[126]. - The ending balance of cash and cash equivalents was 26,835,701.89 yuan, down from 29,700,291.40 yuan in the previous period[126]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,036,540,489.19, a decrease of 1.09% from CNY 1,047,997,444.15 at the end of the previous year[20]. - Current liabilities decreased from CNY 83,550,252.54 to CNY 56,150,826.70, a reduction of about 32.8%[109]. - The total liabilities decreased from CNY 118,296,988.30 to CNY 90,897,562.46, a reduction of approximately 23.1%[109]. - The company's cash and cash equivalents decreased from 46,216,401.31 RMB to 26,835,701.89 RMB during the reporting period[107]. - Accounts receivable decreased from 141,831,187.28 RMB to 108,992,224.40 RMB[107]. - Inventory increased from 47,369,982.96 RMB to 55,182,850.07 RMB[107]. - The total current assets decreased from CNY 293,842,935.29 to CNY 289,489,017.54, a decline of approximately 1.2%[110]. Shareholder Information - The company plans not to distribute cash dividends or issue new shares from capital reserves for the half-year period[53]. - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profits achieved each year over the next three years, with a cumulative cash distribution of at least 30% of the average distributable profits over these three years[81]. - The cash dividend proportion will be at least 80% if the company is in a mature stage without significant capital expenditure, and at least 40% if there are major capital expenditures planned[81]. - The total number of shares before the change was 507,509,800, with 20.49% being restricted shares[88]. - The number of unrestricted shares increased from 403,542,000 (79.51%) to 405,247,313 (79.85%) due to the release of 1,705,313 shares[88]. - The company released 1,705,313 shares from lock-up on January 4, 2016, which corresponds to 25% of the total shares held by directors and executives[88]. - The largest shareholder, Huang Xiaobiao, holds 11.44% of the shares, totaling 58,083,001 shares[95]. - The second-largest shareholder, Chen Yonghong, holds 10.94% of the shares, totaling 13,885,250 shares, which are pledged[95]. Operational Strategy - The company plans to enhance its marketing system and brand development, focusing on core products such as Shuangliao Houfeng San and Zhonggan Ling Pian[28]. - The decline in revenue and profit was primarily due to adjustments in the pharmaceutical distribution business of its subsidiary, Jiaying Pharmaceutical, and a decrease in sales from Jinsha Pharmaceutical[28]. - The company has a strong competitive advantage with its proprietary products, including patented traditional Chinese medicines, which have established brand recognition and market share[37]. Compliance and Governance - The company confirms its ability to continue as a going concern for the next 12 months from the reporting date[149]. - The financial statements are prepared based on the going concern principle and comply with the accounting standards issued by the Ministry of Finance[148][151]. - The company aims to maintain compliance with legal and regulatory requirements in all transactions[79]. - The company has committed to avoiding any business competition with its subsidiaries during the shareholder period[79]. Accounting Policies - The company adopts Renminbi as its functional currency for accounting purposes[154]. - The company’s consolidated financial statements include all subsidiaries under its control, reflecting the overall financial status and performance of the group[157][158]. - Cash and cash equivalents are defined as cash on hand and deposits that can be used for payment at any time, with investments meeting specific criteria classified as cash equivalents[164]. - Financial instruments include financial assets, financial liabilities, and equity instruments, classified at initial recognition based on their nature[167].

广东嘉应制药股份有限公司 2016 年第一季度报告正文 证券代码：002198 证券简称：嘉应制药 公告编号：2016-013 广东嘉应制药股份有限公司 2016 年第一季度报告正文 广东嘉应制药股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)钟苑苑声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 1 对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目，以及把《公 开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应 说明原因 ...

广东嘉应制药股份有限公司 2015 年年度报告全文 广东嘉应制药股份有限公司 2015 年年度报告 2016-005 2016 年 04 月 1 广东嘉应制药股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)方钦雄声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来发展陈述，属于计划性事项，均不构成公司对投资 者的实质承诺，敬请广大投资者注意投资风险。 可能存在主导产品较为集中、经营成本增加、行业竞争加剧、行业政策变 化等风险，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 5 | | --- | --- | | 第二节 | 公司简介和主要财务指标 9 | | 第三节 | 公司业务概要 12 | ...

Financial Performance - Operating revenue for the reporting period was CNY 98,206,877.54, a decrease of 25.86% year-on-year, while revenue for the year-to-date period was CNY 318,637,415.94, down 19.32%[7] - Net profit attributable to shareholders for the reporting period was CNY 9,723,109.26, a decline of 48.44% year-on-year, with year-to-date net profit at CNY 41,575,589.58, down 17.80%[7] - The basic earnings per share for the reporting period was CNY 0.0192, a decrease of 48.39% compared to the same period last year[7] - The net profit attributable to shareholders for 2015 is expected to range from 58 million to 70 million CNY, representing a decrease of 21.25% to 4.96% compared to the previous year[26] - The net profit for 2014 was reported at 73.65 million CNY, indicating a decline in performance primarily due to adjustments in the pharmaceutical distribution business and a reduction in government subsidies received[27] Assets and Liabilities - Total assets at the end of the reporting period decreased by 3.00% to CNY 1,004,230,532.01 compared to the end of the previous year[7] - Accounts receivable decreased by 33.33% compared to the beginning of the year, primarily due to the recovery of receivables from pharmaceutical distribution[14] - Other receivables increased by 266.02% compared to the beginning of the year, mainly due to increased advances for market development[14] - Long-term equity investments increased by 60.78% compared to the beginning of the year, attributed to additional investments in Huqingyuan and increased investment income[14] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 15,905,091.08, down 80.32%[7] - Cash received from operating activities decreased by CNY 26.07 million, a decline of 82.82%, mainly due to a reduction in receivables[17] - Cash paid for purchasing goods and services increased by CNY 38.63 million, a growth of 50.18%, mainly due to increased payments for pharmaceutical distribution[17] - Cash received from investment activities increased by CNY 16 million, a growth of 100.00%, mainly from the recovery of principal from financial products[18] - Cash paid for fixed assets and other long-term assets decreased by CNY 54.37 million, a decline of 77.27%, mainly due to reduced investment in the second phase of the project[18] - Cash paid for debt repayment increased by CNY 17.20 million, a growth of 114.67%, mainly due to increased bank loan repayments[19] - Cash paid for dividends and interest decreased by CNY 18.93 million, a decline of 92.15%, mainly due to last year's cash dividend distribution[19] - Cash received from financing activities increased by CNY 3.31 million, a growth of 64.07%, mainly due to increased recovery of bank acceptance bill deposits[19] - Cash paid for other financing activities decreased by CNY 16.37 million, a decline of 100.00%, as there were no bank acceptance bills issued this period[19] Shareholder Commitments and Governance - The company has committed to avoiding any competition with its subsidiaries during the shareholder period[23] - Transactions with related parties will follow principles of equality, voluntariness, and fairness[23] - The company will ensure that no illegal transfer of funds or profits occurs through transactions[23] - Shareholders have pledged not to engage in any competing business activities during their tenure[23] - The company will adhere to legal procedures and disclosure obligations for related transactions[23] - The commitment letter from shareholders is legally binding and ensures compensation for any economic losses caused[23] - The company has committed to a legal obligation to ensure fair pricing in transactions with independent third parties to protect the interests of shareholders[24] - The company will not engage in any business activities that may harm its interests during the tenure of its directors and senior management[24] Dividend Policy - The company commits to distributing at least 10% of the annual distributable profit in cash dividends over the next three years, with a cumulative cash distribution not less than 30% of the average annual distributable profit for the three years[25] - In mature development stages without significant capital expenditure plans, the cash dividend proportion should be at least 80% of the profit distribution[25] - The company plans to actively pursue cash profit distribution in accordance with relevant laws and regulations, ensuring a sustainable return to shareholders[25] Other Financial Information - The company received government subsidies totaling CNY 3,530,000 during the reporting period[8] - Operating costs decreased by CNY 69.34 million, a decline of 42.12%, mainly due to the decrease in pharmaceutical distribution business[16] - Investment income increased by CNY 2.447 million, a growth of 942.27%, primarily from the disposal of Renkang Pharmaceutical and equity investment income from Huqingyuan[16] - The stock price for the current issuance is set at 8.31 CNY per share[22] - The compensation obligation for shareholders is based on the net profit after deducting non-recurring gains and losses[22] - A impairment test will be conducted on the equity of Jinsha Pharmaceutical at the end of the compensation period[22] - If the impairment amount exceeds the compensation shares ratio, cash compensation will be required[22] - The company has no securities investments or holdings in other listed companies during the reporting period[28][29] - There are no instances of non-operating fund occupation by controlling shareholders or their affiliates reported during the period[31] - The company has not reported any violations regarding external guarantees during the reporting period[30]

广东嘉应制药股份有限公司 2015 年半年度报告全文 广东嘉应制药股份有限公司 2015 年半年度报告 2015-032 2015 年 08 月 1 广东嘉应制药股份有限公司 2015 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)方钦雄声明：保证本半年度报告中财务报告的真实、准确、完整。 本报告中如有涉及未来发展陈述，属于计划性事项，均不构成公司对投资 者的实质承诺，敬请广大投资者注意投资风险。 2 | 目录 | | --- | | 2015 | 半年度报告 1 | | --- | --- | | 第一节 | 重要提示、目录和释义 2 | | 第二节 | 公司简介 5 | | 第三节 | 会计数据和财务指标摘要 7 | | 第四节 | 董事会报告 9 | | 第五节 | 重要事项 ...

广东嘉应制药股份有限公司 2015 年第一季度报告正文 广东嘉应制药股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)方钦雄声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2015 年第一季度报告正文 证券代码：002198 证券简称：嘉应制药 公告编号：2015-018 广东嘉应制药股份有限公司 2015 年第一季度报告正文 1 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 103,997,545.96 | 126,234,428.13 | -17.62% ...

广东嘉应制药股份有限公司 2014 年第三季度报告正文 证券代码：002198 证券简称：嘉应制药 公告编号：2014-044 广东嘉应制药股份有限公司 2014 年第三季度报告正文 1 广东嘉应制药股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主管人员)方钦雄声明：保证 季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,018,289,379.88 | 919,003,084.87 ...

Financial Performance - The company achieved operating revenue of CNY 262,464,778.41, an increase of 327.47% compared to the same period last year[19]. - The net profit attributable to shareholders was CNY 31,721,790.87, representing a growth of 330.09% year-on-year[19]. - The net cash flow from operating activities reached CNY 53,934,698.49, up 769.31% from the previous year[19]. - The basic earnings per share increased to CNY 0.0625, a rise of 247.22% compared to the same period last year[19]. - The company reported a net profit of ¥3,172.18 million, up 330.09% from the previous year, successfully achieving its annual operational goals[34]. - The company reported a total comprehensive income of ¥31,721,790.87, significantly higher than ¥7,375,569.40 from the previous period, indicating a growth of approximately 330%[117]. - The company reported a net profit of ¥31,721,790.87 for the period, a significant increase compared to the previous year's profit[130]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 970,354,308.17, reflecting a 5.59% increase from the end of the previous year[19]. - Total liabilities increased to CNY 148,940,909.51 from CNY 109,346,490.44, which is an increase of approximately 36.29%[111]. - Shareholders' equity rose to CNY 821,413,398.66 from CNY 809,656,594.43, representing an increase of about 1.09%[111]. - The total owner's equity at the end of the period was ¥821,413,390.00, reflecting growth from the previous year's total[134]. Research and Development - The company is focusing on the development of new drugs, including a project for an anti-tumor nano drug in collaboration with Jinan University[27]. - The company has entered the second phase of clinical trials for a new drug, Sangpi Capsule, aimed at treating type II diabetes[27]. - Research and development expenses totaled ¥8,912,958.08, with a focus on the development of new anti-tumor nano-drug projects and R&D costs from the consolidation of Jinsan Pharmaceutical[32]. - The company has made substantial investments in new drug development, including innovative diabetes treatments and anti-influenza medications, reflecting its commitment to R&D[38]. Marketing and Business Expansion - The company has expanded its marketing efforts and added new pharmaceutical distribution business to boost performance[27]. - The company plans to expand its market presence in rural and community healthcare sectors, leveraging its cost-effective and high-quality products[37]. - Jinsan Pharmaceutical's products, including unique offerings like "Jiesu Qili Pian," have gained significant market acceptance and brand recognition, enhancing competitive advantages[38]. Dividends and Shareholder Returns - The company will not distribute cash dividends or bonus shares for this reporting period[5]. - The company distributed cash dividends of ¥0.80 per share, totaling ¥20,300,393.92, based on a total share capital of 253,754,924 shares[53]. - The company plans to distribute cash dividends amounting to no less than 30% of the average distributable profit over the next three years, with a principle of annual cash distribution[85]. Equity and Share Capital - The company’s total share capital increased from 253,754,924 shares to 507,509,848 shares following a capital reserve conversion plan, where every 10 shares resulted in an additional 10 shares being issued[92]. - The company issued 48,754,924 shares to acquire 64.466% equity of Hunan Jinsida Pharmaceutical Co., Ltd., resulting in a total share capital of 253,754,924 shares as of December 31, 2013[145]. Corporate Governance and Compliance - The company has not engaged in any significant non-public fundraising investment projects during the reporting period[51]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[98]. - The company has no penalties or rectifications during the reporting period, indicating compliance with regulations[86]. - The company guarantees that it will not use its shareholder rights to manipulate or instruct the management of its subsidiaries[83]. Cash Flow Management - The company experienced a net cash outflow from financing activities of ¥19,545,741.36, compared to a net outflow of ¥26,223,147.69 in the previous period, indicating an improvement in cash flow management[124]. - Cash received from operating activities totaled ¥76,186,035.75, an increase of 39.9% from ¥54,503,942.81 in the previous period[127]. - The total cash and cash equivalents at the end of the period reached ¥18,588,558.47, compared to ¥895,525.48 at the end of the previous period, reflecting a substantial increase of 1985.5%[128]. Financial Reporting and Accounting Policies - The company’s financial statements comply with the requirements of the enterprise accounting standards, reflecting the financial status, operating results, and cash flows accurately[148]. - The company follows consistent accounting policies and periods for all subsidiaries included in the consolidated financial statements, making necessary adjustments if discrepancies exist[159]. - The company recognizes the fair value of remaining equity investments at the loss of control date when it disposes of a subsidiary[161]. Shareholder Compensation and Obligations - If the actual net profit falls below the predicted net profit, the shareholders will compensate the difference through share repurchase, with a maximum of 48,754,924 shares available for compensation[82]. - The company is committed to fulfilling the compensation obligations as per the agreements made with the shareholders[82]. - The compensation obligations are individual to each shareholder, with no joint liability among them[82].

广东嘉应制药股份有限公司 2014 年半年度报告全文 广东嘉应制药股份有限公司 2014 年 08 月 1 广东嘉应制药股份有限公司 2014 年半年度报告全文 第一节 重要提示、目录和释义 2014 年半年度报告 2014-037 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)方钦雄声明：保证本半年度报告中财务报告的真实、准确、完整。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介 5 | | 第三节 会计数据和财务指标摘要 7 | | 第四节 董事会报告 9 | | 第五节 重要事项 16 | | 第六节 股份变动及股东情况 25 | | 第七节 优先股相关情况 28 | | 第八节 董事、监事、高级管理人员情况 29 | | 第九节 财务报告 31 | | 第十节 备查文件目录 128 | ...

所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)方钦雄声明：保证季度报告中财务报表的真实、准确、完整。 1 广东嘉应制药股份有限公司 2014 年第一季度报告正文 第一节 重要提示 广东嘉应制药股份有限公司 2014 年第一季度报告正文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 证券代码：002198 证券简称：嘉应制药 公告编号：2014-023 广东嘉应制药股份有限公司 2014 年第一季度报告正文 √ 适用 □ 不适用 单位：元 2 广东嘉应制药股份有限公司 2014 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 126,234,428. ...